Biotech | April 11, 2022
Lonza signs manufacturing deal with Asher Biotherapeutics
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Company to manufacture drug substance for clinical supply of HaemaLogiX’s lead multiple myeloma drug candidate, KappaMab, at its new state-of-the-art facility in Guangzhou, China
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)